EPIRUS’ BOW-015 achieves bioequivalence to Remicade in a single dose comparator trial

EPIRUS Biopharmaceuticals, Inc., formerly known as fourteen22 Inc, announced that its lead asset, BOW-015, achieved bioequivalence to Remicade in a single dose comparator trial.

Read more...

No comments:

Post a Comment

8 Ways to Trick Yourself Thin

8 Ways to Trick Yourself Thin An article from By Chris Freytag The formula for weight loss may be simple-take in fewer calories ...